Dexi Liu, the Panoz Professor of Pharmacy and head of the department of pharmaceutical and biomedical sciences, College of Pharmacy, is co-founder of Lynkogen, Inc., a pre-clinical stage biotechnology startup company developing protein-based pharmaceutics for the treatment of obesity, fatty liver, and other metabolic diseases. Liu’s new venture was launched to support the commercialization of a protein drug developed in his laboratory, which combines a drug that mimics the natural hormone incretin with an anti-inflammatory, to help patients lose weight and combat Nonalcoholic Steatohepatitis (NASH), and Non-Alcoholic Fatty Liver Disease (NAFLD).